Src-Homology 2 Domain-Containing Phosphatase 2 in Resected EGFR Mutation-Positive Lung Adenocarcinoma
Ito, Masaoki (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Codony-Servat, Jordi (Institut Universitari Dexeus)
Giménez-Capitán, Ana (Institut Universitari Dexeus)
Serra-Mitjans, Mireia (Hospital Universitari MútuaTerrassa (Terrassa, Catalunya))
Pérez-Ochoa, Francisco (Hospital Universitari MútuaTerrassa (Terrassa, Catalunya))
Llige, David (Institut Germans Trias i Pujol)
Chaib, Imane (Institut Germans Trias i Pujol)
Rami-Porta, Ramon (Hospital Universitari MútuaTerrassa (Terrassa, Catalunya))
Obiols, Carme (Hospital Universitari MútuaTerrassa (Terrassa, Catalunya))
Call, Sergi (Universitat Autònoma de Barcelona. Departament de Ciències Morfològiques)
Iglesias, Manuela (Hospital Universitari MútuaTerrassa (Terrassa, Catalunya))
Belda, José (Belda Sanchis) (Hospital Universitari MútuaTerrassa (Terrassa, Catalunya))
Tarroch-Sarasa, Xavier (Hospital Universitari MútuaTerrassa (Terrassa, Catalunya))
Karachaliou, Niki (Institut Universitari Dexeus)
Molina-Vila, Miguel Ángel (Institut Universitari Dexeus)
Okada, Morihito (Hiroshima University. Department of Surgical Oncology)
Rosell, Rafael (Institut Germans Trias i Pujol)

Fecha:	2020
Resumen:	EGFR mutation-positive lung adenocarcinoma (LUAD) displays impaired phosphorylation of ERK and Src-homology 2 domain-containing phosphatase 2 (SHP2) in comparison with EGFR wild-type LUADs. We hypothesize that SHP2 expression could be predictive in patients positive with resected EGFR mutation versus patients with EGFR wild-type LUAD. We examined resected LUAD cases from Japan and Spain. mRNA expression levels of AXL, MET, CDCP1, STAT3, YAP1, and SHP2 were analyzed by quantitative reverse transcriptase polymerase chain reaction. The activity of SHP2 inhibitors plus erlotinib were tested in EGFR -mutant cell lines and analyzed by cell viability assay, Western blot, and immunofluorescence. A total of 50 of 100 EGFR mutation-positive LUADs relapsed, among them, patients with higher SHP2 mRNA expression revealed shorter progression-free survival, in comparison with those having low SHP2 mRNA (hazard ratio: 1. 83; 95% confidence interval: 1. 05-3. 23; p = 0. 0329). However, SHP2 was not associated with prognosis in the remaining 167 patients with wild-type EGFR. In EGFR -mutant cell lines, the combination of SHP099 or RMC-4550 (SHP2 inhibitors) with erlotinib revealed synergism via abrogation of phosphorylated AKT (S473) and ERK1/2 (T202/Y204). Although erlotinib translocates phosphorylated SHP2 (Y542) into the nucleus, either RMC-4550 alone, or in combination with erlotinib, relocates SHP2 into the cytoplasm membrane, limiting AKT and ERK1/2 activation. Elevated SHP2 mRNA levels are associated with recurrence in resected EGFR mutation-positive LUADs, but not in EGFR wild-type. EGFR tyrosine kinase inhibitors can enhance SHP2 activation, hindering adjuvant therapy. SHP2 inhibitors could improve the benefit of adjuvant therapy in EGFR mutation-positive LUADs.
Nota:	Funding: supported by a La Caixa Foundation grant and the Spanish Association Against Cancer (PROYE18012ROSE)
Derechos:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Lengua:	Anglès
Documento:	Article ; recerca ; Versió publicada
Materia:	Lung adenocarcinoma ; EGFR ; SHP2 ; Surgery ; Recurrence
Publicado en:	JTO Clinical and Research Reports, Vol. 1 Núm. 4 (august 2020) , ISSN 2666-3643

DOI: 10.1016/j.jtocrr.2020.100084
PMID: 34589963

11 p, 2.1 MB

El registro aparece en las colecciones:
Documentos de investigación > Documentos de los grupos de investigación de la UAB > Centros y grupos de investigación (producción científica) > Ciencias de la salud y biociencias > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP)
Artículos > Artículos de investigación
Artículos > Artículos publicados